Navigation Links
Anti-Clotting Drug Trial Shortened by Bleeding Problems
Date:1/24/2008

But study author says medication could help many avoid stroke

THURSDAY, Jan. 24 (HealthDay News) -- A study of the new anti-clotting drug idraparinux for preventing strokes was stopped early because of excess bleeding, a problem that has plagued the medication.

But the researchers said the trial could open the way to at least limited use of the drug.

The bleeding problem seems to occur primarily in two groups of people -- those over 70 and those with kidney impairment, said study lead author Dr. Harry R. Buller, chairman of the department of vascular medicine at the Academic Medical Center in Amsterdam, the Netherlands.

"We have started a new study in which we have adapted the dose for persons with renal [kidney] impairment," Buller said. "This is another chance to show that this concept is alive."

Idraparinux is one of a number of anti-clotting agents being tested as possible replacements for the current standby warfarin (Coumadin), which is highly effective but difficult to manage, requiring frequent blood tests.

Buller is an idraparinux enthusiast. "Its beauty is twofold," he said. "It uses the body's natural defenses, and it can be given once a week. But much to our regret, particularly in persons over 70 or with some kind of renal impairment, the concentration of the drug builds up, and there is excessive bleeding."

The new study was stopped after enrollment of 4,576 people with atrial fibrillation -- an irregular heartbeat -- after excess bleeding occurred in 19.7 percent of those given weekly injections of idraparinux, compared to 11.3 percent of those taking other anti-clotting agents.

The findings were published in the Jan. 26 issue of The Lancet.

To outside observers, that was a depressing repeat of studies, reported last September, that showed the drug to be effective against deep vein thrombosis and long-term prevention of blood clots but with a high rate of serious bleeding complications.

"This is clearly a setback," said Dr. Alan Go, associate director for clinical research at Kaiser Permanente of Northern California, co-author of an accompanying editorial in the journal.

Go, like other experts in the field, acknowledged that "we are eager to find a replacement for warfarin. It is a remarkably effective drug but challenging to deliver and challenging to take."

Buller said that if all turns out as well as he hopes, idraparinux could be a useful alternative for many people who could get the needed anti-clotting activity with a single weekly injection, while forgoing the constant blood tests required for warfarin users.

"That might lead to some effective agent," Go said. "It's certainly possible, and I wouldn't rule it out. But we would need another large trial to prove it."

Idraparinux is not the only anti-clotting medication in the race to supplant warfarin, Go noted. "At least two oral inhibitors are being tested," he said. "There are different approaches to affecting clotting factors, and there is a very aggressive drive to find something to replace warfarin."

Buller said: "The primary question is, can this drug replace warfarin in preventing stroke? The answer, I think, is yes, but not in subgroups of individuals."

More information

You can learn about the role of anti-clotting drugs in preventing strokes from the Heart Rhythm Society.



SOURCES: Harry R. Buller, M.D., chairman, department of vascular medicine, Academic Medical Center, Amsterdam, the Netherlands; Alan Go, M.D., associate director for clinical research, Kaiser Permanente of Northern California, Oakland; Jan. 26, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Possible safer target for anti-clotting drugs found
2. New Anti-Clotting Drug Shows Promise in Heart Patients
3. Researchers identify molecules with interesting anti-clotting properties
4. New Heart Pump Shows Promise in Trial
5. Trial to Test Gene Therapy for Angina in Women
6. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
7. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. MDS Pharma Services Wins Award for Management of Global Malaria Trial
10. New Ovarian Cancer Drug Trial Under Way
11. Study Questions Dead-End Cancer Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anti-Clotting Drug Trial Shortened by Bleeding Problems
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: